ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round

Articles | November 23, 2020

ATAI Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 million Series C financing round, including $32 million of its 2020 convertible debt that converted in connection with the Series C. Read More

Substance Use Disorder

Mission | November 16, 2020

Substance Use Disorders (SUDs) are highly prevalent disorders that are characterized by an inability to control the use of a legal or illegal drug, medication or other psychoactive compound. SUDs typically occur following prolonged, repeated use of a substance at high doses and/or high frequencies and can lead to significant… Read More

Anxiety

Mission | November 16, 2020

Anxiety is considered a common aspect of life, however anxiety disorders develop when feelings of apprehension and unease persist over an extended period and potentially worsen over time. Anxiety disorders, which are believed to stem from a set of risk factors including genetics, neurochemistry, life experiences and personality, can have… Read More

Depression

Mission | November 16, 2020

Today, the World Health Organization World Health Organization estimates that approximately 322 million people live with depression, making it both the most common mental health disorder and the leading cause of disability worldwide.  It is also one of the most financially costly: In 2013 alone, depression robbed the global market… Read More

ATAI’s Chief Scientific Officer joins leaders in psychedelic medicine at Mapping the Mind

News | November 9, 2020

Last week, Srinivas Rao, MD, Chief Scientific Officer of ATAI Life Sciences, took to the stage alongside other leaders in psychedelic medicine at the 2019 Mapping the Mind conference in Toronto. The conference, which featured speakers like Dr. David Nichols, founding president of the Heffter Insitute, and Dr. Matthew Johnson, associate director… Read More

GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders

News | November 9, 2020

NEWPORT BEACH, CA and BERLIN, GERMANY – Today, GABA Therapeutics, a biotech company focused on the treatment of mood disorders, and ATAI Life Sciences, a global biotech company builder working on paradigm shifting interventions for unmet needs in the mental health space, announced a partnership to develop a novel compound that… Read More

ATAI Life Sciences Partners with Neuronasal Inc. to Develop Novel Treatment for mild Traumatic Brain Injury (mTBI)

Articles | November 8, 2020

ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that envisions an end to mental illnesses, today announced that it has partnered with Neuronasal Inc., to develop a short-term treatment for mild Traumatic Brain Injury (mTBI) or concussion. Read More

ATAI launches IntroSpect Digital Therapeutics, appoints veteran software engineer David Keene as CEO

Articles | November 8, 2020

Today, ATAI Life Sciences (“ATAI” or the “Company”), a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of its digital therapeutic platform IntroSpect Digital Therapeutics, Inc. (“IntroSpect”). David Keene, who brings almost two decades of experience in tech- and healthcare-related fields, will serve as CEO… Read More

ATAI Life Sciences launches EmpathBio to treat post-traumatic stress disorder with novel MDMA product

Articles | November 8, 2020

Today, ATAI Life Sciences, a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of EmpathBio, a wholly-owned subsidiary developing derivatives of  3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications. Read More

ATAI Life Sciences Announces Joint Venture with DemeRx to Develop Ibogaine For Opioid Use Disorder

Articles | November 8, 2020

 ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that envisions an end to mental illnesses, today announced an investment in two separate joint ventures (JV) with DemeRx, a clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for the treatment of opioid… Read More